Research
Hormonal
GLP-1 receptor agonists and SGLT2 inhibitors are underutilized in specialist diabetes clinics for patients with BMI ≥ 35 kg/m2, despite guidelines recommending their use for weight-lowering effects.
Ask your doctor about GLP-1 agonists or SGLT2 inhibitors if you have Type 2 Diabetes and are overweight. These drugs help with weight loss and blood sugar control, unlike older medications that can cause weight gain.
GoodQualifiesHIGH confidence
In our BMI ≥ 35 kg/m2 group, use of weight-lowering medications was limited with less than 1 in 5 participants on a GLP1 agonist and only a quarter on an SGLT2 inhibitor.
Why this rating
Direct observation of prescription rates in a large cohort.
Source
Severe obesity in a specialist type 2 diabetes outpatient clinic: an Australian retrospective cohort study
Arunav Thakur et al. · BMC Endocrine Disorders · 2021
DOI 10.1186/s12902-021-00722-9
cohort · n=700Cited 6×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →